However, the viability of CD34+/CML cells in the rosuvastatin and IM combination treatment group was significantly lower than that in the IM (p < 0.01) and rosuvastatin single treatment groups (p < 0.001). Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.